Previous 10 | Next 10 |
Data demonstrates that MIBC patients who remain Signatera MRD-negative after surgery may be spared from adjuvant treatment, with 100% overall survival at 12 months Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 ...
2024-04-03 15:44:21 ET More on Natera Natera: Capitalizing On The Positive Momentum Of Personalized Medicine Natera, Inc. (NTRA) Q4 2023 Earnings Call Transcript Natera GAAP EPS of -$0.65 beats by $0.06, revenue of $311.1M beats by $23.78M Natera Q4 2023 Earn...
2024-04-01 08:42:12 ET Natera ( NASDAQ: NTRA ) and the Alliance for Clinical Trials in Oncology, part of the National Clinical Trials Network funded by the National Cancer Institute announced the launch of Alliance A032103, a randomized, phase II/III, biomarker-integrated trial. ...
First of its kind study in muscle-invasive urothelial cancer, with both escalation and de-escalation arms Approximately 1,000 patients will be enrolled at more than 300 sites Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, and the Alliance for Clinical...
2024-03-28 13:46:05 ET More on Invesco S&P 500 Equal Weight ETF: RSP: Equal Weighting The S&P 500 To Minimize Magnificent Seven Exposure Is Not Optimal RSP: I Firmly Believe In An Allocation To Equal-Weight At This Juncture RSP: Happy 2024! Don't Make Decisio...
2024-03-22 15:27:11 ET Summary The global market size for personalized medicines is estimated to reach $1,233.23 billion by 2033, with North America experiencing significant growth in the oncology sector. Natera Inc., a diagnostic company, focuses on women's health, oncology, and ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a collaboration with the Fédération Francophone de Cancérologie Digestive and CHU Dijon Bourgogne on the CIRCULATE-PRODIGE-70 study, a randomized, multicenter, prospective phase III clinical tr...
2024-03-14 12:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Supports broader adoption of Natera’s Renasight TM test Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, commented today on the 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease , which was recently publ...
2024-03-13 14:01:40 ET More on Qiagen, Bio-Techne, etc. Qiagen N.V. 2023 Q4 - Results - Earnings Call Presentation Qiagen N.V. (QGEN) Q4 2023 Earnings Call Transcript Bio-Techne Corporation (TECH) Q2 2024 Earnings Call Transcript Qiagen upgraded at Morgan Sta...
News, Short Squeeze, Breakout and More Instantly...
Expanded EBLIS study with up to 12 years of clinical follow-up across all subtypes of breast cancer Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its pers...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2024, after the market close on May 9, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4...
Backed by large clinical validation study with over 650 RhD-negative patients with confirmed outcomes, resulting in 100% sensitivity and >99% specificity Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new...